echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Treatment or new progression of advanced neuroendocrine tumors! Hutchison Whampoa has submitted a marketing authorization application forUrufatinib to the EMA.

    Treatment or new progression of advanced neuroendocrine tumors! Hutchison Whampoa has submitted a marketing authorization application forUrufatinib to the EMA.

    • Last Update: 2020-08-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Hutchison Whampoa China Pharmaceutical Technology Co., Ltd. (Chi-Med) announced today that it has obtained scientific advice from the European Medicines Agency (EMA) Human Medicines Board (CHMP) for the treatment of advanced neuroendocrine tumors (NET).
    completed SANET-ep (Non-Pancreatic NET) and SANET-p (Pancreatic NET) studies, as well as data support marketing authorization applications (MAA) for non-pancreatic and pancreatic NET patients in the United States.
    Hutchison Whampoa plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2021.
    Urufatinib is a new type of oral vascular immunokinase inhibitor that selectively inhibits tyrosine kinase activity associated with vascular endotoriasis factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR), and Surufatinib regulates tumor-related macrophages to promote the body's immune response to tumor cells.
    U.S., Surufatinib was awarded the fast-track title of Treatment NET in April 2020 and the Orphan Drug for Pancreatic NET in November 2019.
    , China's National Drug Administration (NMPA) began reviewing Surufatinib's NDA for the treatment of patients with advanced non-pancreatic NET in November 2019.
    The progress was supported by DATA from the SANET-ep study, a Phase III study of Surufatinib's treatment of non-pancreatic NET patients in China, and a mid-term analysis of 198 patients in June 2019 showed that Surufatinib significantly extended patients' progression-free survival (PFS).
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.